Does NELVUTAMIG Cause Immune-mediated hepatic disorder? 14 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Immune-mediated hepatic disorder have been filed in association with NELVUTAMIG. This represents 5.1% of all adverse event reports for NELVUTAMIG.
14
Reports of Immune-mediated hepatic disorder with NELVUTAMIG
5.1%
of all NELVUTAMIG reports
0
Deaths
2
Hospitalizations
How Dangerous Is Immune-mediated hepatic disorder From NELVUTAMIG?
Of the 14 reports, 2 (14.3%) required hospitalization.
Is Immune-mediated hepatic disorder Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NELVUTAMIG. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does NELVUTAMIG Cause?
Off label use (29)
Immune-mediated hepatitis (18)
Hypothyroidism (17)
Immune-mediated enterocolitis (16)
Malignant neoplasm progression (16)
Colitis (15)
Drug ineffective (14)
Fatigue (13)
Immune-mediated myocarditis (11)
Diarrhoea (10)
What Other Drugs Cause Immune-mediated hepatic disorder?
PEMBROLIZUMAB (923)
NIVOLUMAB (486)
IPILIMUMAB (318)
CARBOPLATIN (188)
PACLITAXEL (144)
DURVALUMAB (102)
LENVATINIB (100)
PEMETREXED (67)
AXITINIB (53)
CABOZANTINIB S-MALATE (45)
Which NELVUTAMIG Alternatives Have Lower Immune-mediated hepatic disorder Risk?
NELVUTAMIG vs NEMOLIZUMAB
NELVUTAMIG vs NEMOLIZUMAB-ILTO
NELVUTAMIG vs NEOMYCIN
NELVUTAMIG vs NEORAL
NELVUTAMIG vs NEOSTIGMINE